利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

46 条记录 (耗时 0.056 秒)

    METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES
    25.
    发明申请
    METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES 审中-公开
    方法，用于治疗相关疾病的测定和组合物

    公开(公告)号：US20120309835A1

    公开(公告)日：2012-12-06

    申请号：US13314035

    申请日：2011-12-07

    申请人： Kenneth Widder ,  Jay Lichter ,  Nathan L. Mata

    发明人： Kenneth Widder ,  Jay Lichter ,  Nathan L. Mata

    IPC分类号： A61K31/16 ,  A61P27/02

    CPC分类号： A61K31/165 ,  A61K31/16 ,  A61K31/56 ,  A61K45/06 ,  G01N2800/042 ,  G01N2800/164 ,  A61K2300/00

    摘要： Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.

    摘要翻译： 本文描述了通过调节受试者中转甲状腺素蛋白（TTR）和视黄醇结合蛋白（RBP）可用性来治疗某些视黄醇相关疾病和病症的方法和组合物。 例如，该方法和组合物提供用于治疗和/或预防年龄相关性黄斑变性和/或营养不良，代谢紊乱，特发性颅内高血压，增生性骨折和蛋白质错折叠和聚集疾病的治疗剂。 所公开的组合物可用作单一药物治疗或与其它药物或疗法组合使用。 此外，本文描述了用于选择可以调节受试者的TTR和RBP可用性的适当试剂的方法和测定法。

    METHODS FOR TREATING NEUROPSYCHIATRIC CONDITIONS
    26.
    发明申请
    METHODS FOR TREATING NEUROPSYCHIATRIC CONDITIONS 审中-公开
    治疗神经病学症状的方法

    公开(公告)号：US20100317715A1

    公开(公告)日：2010-12-16

    申请号：US12745886

    申请日：2008-12-19

    申请人： Benedikt Vollrath ,  Jay Lichter ,  Sergio G. Duron ,  Petpiboon Peppi Prasit

    发明人： Benedikt Vollrath ,  Jay Lichter ,  Sergio G. Duron ,  Petpiboon Peppi Prasit

    IPC分类号： A61K31/713 ,  A61P25/00

    CPC分类号： A61K45/06 ,  A61K31/4365 ,  A61K31/506 ,  A61K31/519 ,  A61K2300/00

    摘要： Provided herein are compositions and methods for treating a subject suffering from Fragile X syndrome, autism, Down's syndrome, mental retardation, or a neuropsychiatric condition (e.g., schizophrenia). The methods include systemic administration of a a therapeutically effective amount of a PAK inhibitor in combination with a Group I mGluR antagonist (e.g., an mGluR5 antagonist). The PAK inhibitor and mGluR antagonist can be administered together, e.g., in one pharmacological composition, or they can be administered separately.

    摘要翻译： 本文提供了用于治疗患有脆性X综合征，自闭症，唐氏综合征，精神发育迟滞或神经精神病状（例如精神分裂症）的受试者的组合物和方法。 所述方法包括联合治疗有效量的PAK抑制剂与I组mGluR拮抗剂（例如，mGluR5拮抗剂）的全身施用。 PAK抑制剂和mGluR拮抗剂可以一起施用，例如在一种药理组合物中，或者它们可以分开施用。

    Detection and analysis of ophthalmically-relevant fluorescent molecules
    29.
    发明申请
    Detection and analysis of ophthalmically-relevant fluorescent molecules 审中-公开
    眼科相关荧光分子的检测和分析

    公开(公告)号：US20060099714A1

    公开(公告)日：2006-05-11

    申请号：US11258504

    申请日：2005-10-25

    申请人： Nathan Mata ,  Kenneth Widder ,  Jay Lichter

    发明人： Nathan Mata ,  Kenneth Widder ,  Jay Lichter

    IPC分类号： G01N33/50

    CPC分类号： A61K31/355 ,  G01N21/6456 ,  G01N21/6486 ,  G01N33/50 ,  G01N2800/16 ,  G01N2800/164 ,  Y10T436/17

    摘要： Disclosed herein are methods and devices for detecting fluorescent molecules that are relevant to the health of the eye and related tissues. The presence of such molecules in the eye and related tissues can be used to diagnose whether the patient has certain diseases, including the macular degenerations and macular dystrophies. The amount of such molecules in the eye and related tissues can be used to determine the extent and stage of these diseases, to monitor the progress of these diseases, to design treatment strategies, to monitor the effectiveness of such treatments and to develop new therapies.

    摘要翻译： 本文公开了用于检测与眼睛和相关组织的健康有关的荧光分子的方法和装置。 这些分子在眼睛和相关组织中的存在可用于诊断患者是否具有某些疾病，包括黄斑变性和黄斑营养不良。 眼睛和相关组织中的这些分子的量可用于确定这些疾病的程度和阶段，监测这些疾病的进展，设计治疗策略，监测这些治疗的有效性并开发新的疗法。